DBV Technologies S.A. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: DBV Technologies S.A.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Late-stage specialty biopharmaceutical company developing Viaskin, an epicutaneous immunotherapy (EPIT) platform for food allergies. The company has no commercial product revenue and relies on equity financing and government grants (French Research Tax Credit).
Key Focus: Advancing Viaskin Peanut Patch for children with peanut allergy toward regulatory approval in the U.S. and EU.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 |
|---|---|---|
| Operating Income | $5.6 | $4.2 |
| Net Loss | $(146.9) | $(113.9) |
| Net Loss Per Share (Basic/Diluted) | $(1.05) | $(1.17) |
| Cash and Cash Equivalents (Year-End) | $194.2 | $32.5 |
| Net Cash Used in Operating Activities | $(121.2) | $(104.5) |
| Net Cash Provided by Financing Activities | $276.2 | $0.6 |
| Accumulated Deficit | $(393.1) | $(286.4) |
Note: Operating income consists entirely of the French Research Tax Credit (CIR). The company generated $0 in product revenue.
Material Changes vs. Prior Period
- Financing Surge: The company raised significant capital in 2025, including a $125.5 million PIPE financing in April and $65 million via an At-The-Market (ATM) program in Q4. Subsequent warrant exercises in January 2026 added another $195 million (partially received by year-end).
- Liquidity Improvement: Cash and cash equivalents increased from $32.5 million in 2024 to $194.2 million in 2025, extending the cash runway into Q2 2027.
- Expense Growth: Total operating expenses rose 26% to $152.7 million. Research and Development (R&D) expenses increased 31% to $116.7 million, driven by a $16.1 million write-down of pre-commercial inventory and increased clinical trial activity (COMFORT Toddlers study).
- Regulatory Milestone: The company announced positive topline results for the Phase 3 VITESSE trial (children ages 4-7) in December 2025, meeting its primary endpoint.
Guidance, Outlook, and Risks
Outlook and Guidance:
- BLA Submission: Plans to submit a Biologics License Application (BLA) for Viaskin Peanut in children ages 4-7 in the first half of 2026.
- Toddlers Program: A supplemental safety study (COMFORT Toddlers) for ages 1-3 is underway, with a BLA submission anticipated in the second half of 2026 under an Accelerated Approval pathway.
- Commercialization: Management is scaling operations to prepare for a potential U.S. launch, including hiring commercial staff and securing manufacturing capacity.
- Capital Requirements: Despite recent financing, the company anticipates continued significant losses and may require additional funding for commercialization.
- Regulatory Uncertainty: Approval is not guaranteed. The company previously received a Complete Response Letter (CRL) in 2020; success depends on FDA acceptance of new data and manufacturing processes.
- Manufacturing Dependence: Reliance on third-party manufacturers (Sanofi for API, Fareva for patches) creates supply chain risks.
- Going Concern: Management has determined that substantial doubt about the company's ability to continue as a going concern is no longer present due to recent financing, but this remains contingent on future funding needs.
Investor Verification Checklist
- Warrant Exercise Status: Verify the final cash proceeds received from the full exercise of ABSA and BS warrants announced in January 2026.
- BLA Timeline: Monitor the actual submission date of the BLA for the 4-7 age group against the H1 2026 target.
- Inventory Write-downs: Review the $16.1 million pre-commercial inventory write-down to understand the extent of capitalization vs. expensing of commercial readiness costs.
- Manufacturing Agreements: Confirm the terms and minimum purchase obligations of the new Supply Agreement with Sanofi and the Manufacturing Agreement with Fareva La Vallée.
- Cash Burn Rate: Assess the monthly cash burn rate post-financing to validate the Q2 2027 runway estimate.